NCT05211167Unknown3 期
A Multicenter, Randomized, Parallel-controlled Phase III Trial Comparing the Efficacy and Safety of Recombinant Erythropoiesis Stimulating Protein Injection (CHO Cell) With Ipbio in Maintenance Therapy in Hemodialysis Patients With Anemia in Chronic Renal Failure
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- hemoglobin concentration
研究概览
简要总结
To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.
详细描述
In this phase 3, open label, active comparator parallel controlled study, patients were randomly assigned to two study groups: one active comparator control group (Human Erythropoietin Injection , maintaining the same dose and frequency administrated in the sceening period ), and experimental groups (50μg, once every two weeks). All the patients were administered intravenously for 32 weeks and were evaluated the efficacy, safety and pharmacokinetic characteristics. During the whole study period, dosage adjustment was not allowed in the first 4 weeks, while in the remaining trial period dosage adjustment was allowed once every two weeks if necessary.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteer as a subject must understand the study procedure and sign the informed consent form;
- •18 years old ≤ age ≤ 75 years old when sign ICF, gender is not limited;
- •Patients diagnosed with chronic renal failure anemia were receiving maintenance hemodialysis for at least 3 months and 2-3 times a week; The dialysis frequency was stable and there was no change in the dialysis plan throughout the study period;
- •Before enrollment, patient being treated short-acting EPO stabilization therapy for at least 12 weeks, the average concentration of hemoglobin in the screening period is in the range of 100~120 g/L (including both ends), and the difference is less than 10g/L;
- •Iron status and dialysis status were evaluated within 4 weeks before enrollment to meet the following requirements:
- •Transferrin saturation (TSAT) ≥20% and serum ferritin (SF) ≥200 μg/L; Dialysis parameters: urea clearance index spKt/V≥1.2;
- •Subjects agree to use reliable contraceptives by themselves and their spouses from the screening period to within 3 months after the end of the study;
排除标准
- •Allergic to the investigational drug or any ingredient in the investigational drug or has had a severe allergic reaction to the drug in the past;
- •Except of renal anemia, there are other diseases that cause chronic anemia (such as sickle cell anemia, myelodysplastic syndrome, hematological malignancies, myeloma, hemolytic anemia, pure red blood cell aplastic anemia), blood systemic disease or coagulopathy;
- •Patients who have received or plan to have a kidney transplant during the study period, or who plan to have other surgical procedures during the study period (mainly major surgeries, except those with low blood loss that do not affect Hb concentration);
- •Patients with acute or chronic blood loss (such as upper gastrointestinal bleeding, etc.) within 3 months prior to enrollment were excluded from the scope of hemorrhage caused by minor surgeries such as temporary vascular access required by clinical medical procedures;
- •Patiernts who was suffering from malignant hypertension or poor control of blood pressure (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg);
- •The following conditions (including but not limited to) occurred in the laboratory examination during the screening period, and the investigator judged that the participants were not eligible for inclusion: a) Patients who were positive for HBsAg, anti-HIV, anti-HCV, and Treponema pallidum antibodies; b) The aspartate aminotransferase or alanine aminotransferase is greater than 3 times the upper limit of normal; c) Serum albumin < 35g/L;
- •Patiernts who was suffering from severe secondary hyperparathyroidism (sustained blood iPTH/PTH >1000 ng/L);
- •Patients with previous thromboembolic disease (excluding luminal infarction), history of severe hematopoietic system, and high clotting tendency;
- •Patiernts with severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure (NYHA class III or IV), temporary vascular access, or myocardial infarction or stroke within 3 months before enrollment;
- •A history of malignant neoplasms, except for: basal cell or squamous cell carcinoma of the skin determined to be cured or no recurrence within 5 years, with radical excision, or carcinoma in situ at any site;
- •The researchers identified those with severe infectious disease or chronic, uncontrolled inflammation within the first four weeks of enrollment;
- •All epilepsy or epilepsy history except of childhood febrile seizures, post-traumatic or abstinence single seizures;
- •Those who have received androgen therapy or who have received blood transfusion therapy within the past 8 weeks before enrollment;
- •Patients who had a pacemaker for more than 5 years; If no more than 5 years of cardiac pacemaker working status assessment and test unqualified;
- •3 months as a subject to participate in other new drug clinical trials or to the group when the withdrawal time is shorter than the five half-life of the test drug (whichever is the longest of the two);
- •Subjects were in the middle of pregnancy or lactation at the time of enrollment;
- •Alcohol, drug or drug addicts;
- •Other conditions that may not be suitable for the study as determined by the investigator.
研究组 & 干预措施
Group A
Active Comparator
Intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks
干预措施: Human Erythropoiesis Injection (CHO cell) (Drug)
Group B
Experimental
Intravenous administration,50μg, once every two weeks, for 32 weeks
干预措施: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell) (Drug)
结局指标
主要结局
hemoglobin concentration
时间窗: 25th-32nd week
the amount of change in mean Hb concentration compared with baseline Hb concentration during the evaluation period
次要结局
- proportion of subjects(for 32 weeks)
- mean red blood cell count(25th-32nd week)
- incidence of Human Erythropoietin antibodies and anti-rESP antibodies(for 32 weeks)
- average hemoglobin concentration(25th-32nd week)
- number of dose adjustments(for 32 weeks)
- adverse events(for 32 weeks)
- the ratio of subjects who are adjusted(for 32 weeks)
- maintenance rate(25th-32nd week)
- proportion of times(25th-32nd week)
- mean reticulocyte count(25th-32nd week)
- Area Under the Curve (AUC)(for 32 weeks)
- average weekly dose(25th-32nd week)
- Maximum Plasma Concentration (Cmax)(for 32 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course- Medico-Economic Aspects (Evaluation of Medical Costs Related to the Three Strategies and Evaluation of Cost/Efficacy)NCT00180999Gustave Roussy, Cancer Campus, Grand Paris420
已完成
不适用
The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD PatientsChronic Kidney Disease (CKD)NCT05422755PT. Daewoong Infion200
已完成
3 期
Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.ScoliosisNCT00323752University of British Columbia20
Unknown
3 期
Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune ThrombocytopeniaImmune ThrombocytopeniaNCT03492515Shandong University90
已完成
1 期
Hydroxyurea and EPO in Sickle Cell DiseaseAnemia, Sickle CellSickle Cell DiseaseNCT05451940Julia Xu17